Latest News

Mining stocks have led recently, but they have also fallen much harder than bullion. Cost and volatility differences reveal which fund fits your goals.

A phase III trial missed its primary endpoint but showed a 32% lower death hazard, signaling potential beyond cardiovascular medicine.

Organic property growth accelerated while debt stays locked in at fixed rates through early 2027, creating a potential window for cash flow conversion.

Micron can go on a terrific bull run once again amid favorable conditions in the memory market.

Royalty cash flow needs no drilling spend, so debt paydown and the dividend draw on money the company never has to reinvest.

GTA V made Take-Two investors a fortune, but the price of admission this time is very different.

PolyPid's regained European rights leave it free to pick a partner before the EMA's late-2027 decision, a choice that will shape its reach.

Trading volume ran well above its three-month average as the AI data center operator rode a sector rally, today, Nov. 11, 2026.

Investors may be viewing this company's future as being more dependent on the AI industry than it actually is.

Today, Nov. 11, 2026, SpaceX's stock finished lower ahead of Friday's planned Starship launch.

Cryptocurrencies recovered some of Tuesday's losses as institutional developments and easing selling pressure offered encouraging signs.

California and Texas expansion unlocks reinsurance synergies that may protect margins as Slide scales beyond Florida.

Resolving problem assets and reducing portfolio uncertainty could unlock capital for reinvestment in higher-yielding loans.

Margin expansion and a $730M acquisition in aerial imagery position CoStar to accelerate subscription growth, but sales productivity remains the wildcard.

Two security giants, one physical and one digital, with very different risk profiles and valuation gaps.

Multiyear supply contracts and higher-margin product launches may help position the company to sustain margin expansion amid industry chip shortages.

Higher margins depend on navigating depreciation and raw material headwinds that could pressure profitability even as pricing power improves.

Alcon's defense of its premium lens franchise against competitor trials is the test that will decide whether its growth holds up.

Asset sales and a new Permian deal are shaping debt reduction and buyback plans.

On Nov. 11, 2026, the specialized AI cloud provider's shares rallied as its revenue topped expectations and it lifted its full-year outlook.

One fund holds about 60 drug companies at a lower fee. The other holds 30 biotech names and has a stronger long-term record. Either way, expect some volatility.

First revenue lands as the ARDS trial enters randomized Phase II.

FDA labeling talks are underway ahead of the D-PLEX100 review deadline, with a potential U.S. launch in view.

Petroleo Brasileiro S.A.- Petrobras (NYSE:PBR) raised its 2026 oil production and investment forecasts after reporting record output and stronger cash generation in the third quarter, executives said on the company’s earnings call. The company now expects average oil production of 2.7 million to 2.

Exelixis (NASDAQ:EXEL) is preparing for a regulatory decision on its cancer drug candidate zanzalintinib and expects results from a kidney cancer study in the first quarter of next year, Chief Strategy Officer Andrew Peters said at an investor event. Peters described the company as approaching a tr